1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

NICE Braces For HTA-Related Challenges Posed By UK’s International Recognition Procedure

 
• By Vibha Sharma

The health technology assessment body for England and Wales will need more resources to deal with the ‘surge’ in UK licenses in the early days of the new IRP. While measures are being put in place to mitigate challenges posed by the procedure, there could be long delays in HTA appraisals, more negative NICE decisions and more managed access agreements.

A calendar with an attached red thumbtack with a tape tag and the words save the date written in black marker
NICE process requires early notification of expected regulatory timings to support its technology appraisals program • Source: Shutterstock

The UK’s new International Recognition Procedure (IRP) presents exciting opportunities in terms of earlier licensing of medicines, but also poses big challenges from a health technology assessment perspective that may test the agility of the current system run by the HTA institute, NICE.

The IRP could result in NICE not having clarity on companies’ pipelines, which can make it difficult for the institute...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 
• By Neena Brizmohun

The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 
• By Anabel Costa-Ferreira

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

Why Chiesi’s Raxone Faced A Decade-Long Wait For English Funding

 
• By Eliza Slawther

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 
• By Anabel Costa-Ferreira

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

More from Europe

Danish Probe Could Influence Rethink Of Controversial EU Urban Wastewater Rules

 
• By Francesca Bruce

Some medicines may be subject to price rises that make them unaffordable if the burden of paying for extra wastewater treatment is not more fairly distributed across different industries, the Danish pharmaceutical industry association has warned.

EMA Revives Face-To-Face Oral Explanations In Response To Industry Feedback

 
• By Vibha Sharma

The European Medicines Agency is bringing back in-person oral explanation meetings with drug sponsors on a pilot basis, following industry feedback that direct engagement with its scientific committees is highly valued.

New EU Filings

 
• By Neena Brizmohun

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.